NDC 70710-1049

Abacavir and lamivudine

Abacavir And Lamivudine

Abacavir and lamivudine is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Zydus Pharmaceuticals (usa) Inc.. The primary component is Abacavir Sulfate; Lamivudine.

Product ID70710-1049_15a33374-5321-4c3d-b308-3e4285e3f3f0
NDC70710-1049
Product TypeHuman Prescription Drug
Proprietary NameAbacavir and lamivudine
Generic NameAbacavir And Lamivudine
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2019-03-14
Marketing CategoryANDA / ANDA
Application NumberANDA208990
Labeler NameZydus Pharmaceuticals (USA) Inc.
Substance NameABACAVIR SULFATE; LAMIVUDINE
Active Ingredient Strength600 mg/1; mg/1
Pharm ClassesHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 70710-1049-3

30 TABLET, FILM COATED in 1 BOTTLE (70710-1049-3)
Marketing Start Date2019-03-14
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 70710-1049-3 [70710104903]

Abacavir and lamivudine TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA208990
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-03-14

NDC 70710-1049-9 [70710104909]

Abacavir and lamivudine TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA208990
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-03-14

Drug Details

Active Ingredients

IngredientStrength
ABACAVIR SULFATE600 mg/1

OpenFDA Data

SPL SET ID:85071242-ccf6-43d7-8ee6-87273d21256f
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 602393

    • Pharmacological Class

    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]

    NDC Crossover Matching brand name "Abacavir and lamivudine" or generic name "Abacavir And Lamivudine"

    NDCBrand NameGeneric Name
    0093-5382Abacavir and LamivudineAbacavir and Lamivudine
    35573-402Abacavir and LamivudineAbacavir and Lamivudine
    35573-430Abacavir and LamivudineAbacavir and Lamivudine
    42291-115Abacavir and LamivudineAbacavir and Lamivudine
    42385-962Abacavir and LamivudineAbacavir and Lamivudine
    65862-335Abacavir and LamivudineAbacavir and Lamivudine
    65862-900Abacavir and LamivudineAbacavir and Lamivudine
    66993-482Abacavir and Lamivudineabacavir sulfate and lamivudine
    68180-288Abacavir and LamivudineAbacavir and Lamivudine
    69097-362Abacavir and LamivudineAbacavir and lamivudine
    70518-0715Abacavir and LamivudineAbacavir and Lamivudine
    70710-1049Abacavir and lamivudineAbacavir and lamivudine
    70771-1053Abacavir and lamivudineAbacavir and lamivudine
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.